Virginie Supervie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7371743/publications.pdf

Version: 2024-02-01

40 papers 1,008 citations

394421 19 h-index 434195 31 g-index

42 all docs 42 docs citations

42 times ranked 1723 citing authors

#	Article	IF	CITATIONS
1	Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut, 2021, 70, 1561-1569.	12.1	7
2	Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?. Aids, 2021, 35, 2347-2354.	2.2	3
3	Revealing HIV epidemic dynamics and contrasting responses in two WHO Eastern European countries: insights from modeling and data triangulation. Aids, 2021, 35, 675-680.	2.2	3
4	HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019. Eurosurveillance, 2021, 26, .	7. O	6
5	Identifying key elements to inform HIV-testing interventions for primary care in Belgium. Health Promotion International, 2020, 35, 301-311.	1.8	13
6	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	5.8	16
7	Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. Journal of the International AIDS Society, 2019, 22, e25371.	3.0	12
8	Revealing geographical and population heterogeneity in <scp>HIV</scp> incidence, undiagnosed <scp>HIV</scp> prevalence and time to diagnosis to improve prevention and care: estimates for France. Journal of the International AIDS Society, 2018, 21, e25100.	3.0	50
9	Brief Report: Per Sex-Act Risk of HIV Transmission Under Antiretroviral Treatment: A Data-Driven Approach. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 440-444.	2.1	6
10	HIV testing within general practices in Europe: a mixed-methods systematic review. BMC Public Health, 2018, 18, 1191.	2.9	24
11	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 28-37.	2.1	29
12	Monitoring the HIV continuum of care in key populations across Europe and Central Asia. HIV Medicine, 2018, 19, 431-439.	2.2	19
13	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	5 . 8	46
14	Prevention of treatable infectious diseases: A game-theoretic approach. Vaccine, 2017, 35, 5339-5345.	3.8	7
15	Towards standardized definitions for monitoring the continuum of HIV care in Europe. Aids, 2017, 31, 2053-2058.	2.2	19
16	The diffusion dynamics of choice: From durable goods markets to fashion first names. Complexity, 2016, 21, 362-369.	1.6	6
17	Time for a revolution in tracking the HIV epidemic. Lancet HIV, the, 2016, 3, e337-e339.	4.7	7
18	Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 348-355.	2.1	39

#	Article	IF	CITATIONS
19	Risk of HIV Transmission Under Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e41-e42.	2.1	2
20	GBD 2013 and HIV incidence in high income countries. Lancet, The, 2015, 385, 1177.	13.7	6
21	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. Bulletin of the World Health Organization, 2015, 93, 521-528.	3.3	9
22	Sub-Saharan African migrants living with HIV acquired after migration, France, ANRS PARCOURS study, 2012 to 2013. Eurosurveillance, 2015, 20, .	7.0	57
23	Heterosexual Risk of HIV Transmission per Sexual Act Under Combined Antiretroviral Therapy: Systematic Review and Bayesian Modeling. Clinical Infectious Diseases, 2014, 59, 115-122.	5.8	30
24	The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. Aids, 2014, 28, 1797-1804.	2.2	72
25	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 1388-1399.	3.0	28
26	Immune Responses Driven by Protective Human Leukocyte Antigen Alleles From Long-term Nonprogressors Are Associated With Low HIV Reservoir in Central Memory CD4 T Cells. Clinical Infectious Diseases, 2012, 54, 1495-1503.	5.8	110
27	Undiagnosed HIV prevalence in France. Aids, 2012, 26, 2419.	2.2	1
28	Predicting effect of pre-exposure prophylaxis on HIV epidemics. Lancet, The, 2012, 379, 2423.	13.7	2
29	New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data. Aids, 2011, 25, 1905-1913.	2.2	44
30	Modeling dynamic interactions between pre-exposure prophylaxis interventions & Description amp; treatment programs: predicting HIV transmission & Description amp; resistance. Scientific Reports, 2011, 1, 185.	3.3	48
31	HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. Aids, 2011, 25, 1017-1023.	2.2	37
32	HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12381-12386.	7.1	103
33	Assessing the impact of mass rape on the incidence of HIV in conflict-affected countries. Aids, 2010, 24, 2841-2847.	2.2	26
34	Is there any evidence that syphilis epidemics cycle?. Lancet Infectious Diseases, The, 2008, 8, 577-581.	9.1	20
35	Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data. Mathematical Biosciences, 2007, 209, 90-107.	1.9	8
36	Predicting the future of XDR tuberculosis. Lancet Infectious Diseases, The, 2007, 7, 443.	9.1	32

3

VIRGINIE SUPERVIE

#	Article	IF	CITATIONS
37	The transmission dynamics of syphilis and the CDC's elimination plan. Nature Precedings, 2007, , .	0.1	1
38	BSE Risk Assessment as a Basis for Updating French Screening Policy. Risk Analysis, 2007, 27, 1131-1140.	2.7	3
39	How was the French BSE epidemic underestimated?. Comptes Rendus - Biologies, 2006, 329, 106-116.	0.2	9
40	The unrecognised French BSE epidemic. Veterinary Research, 2004, 35, 349-362.	3.0	43